EVLO Evelo Biosciences Inc.

6.45
+0.44  (+7%)
Previous Close 6.01
Open 5.86
Price To Book 2.57
Market Cap 206,953,597
Shares 32,085,829
Volume 59,998
Short Ratio
Av. Daily Volume 76,556
Stock charts supplied by TradingView

NewsSee all news

  1. Flagship Pioneering Strengthens Leadership With Appointment of Paul Biondi as Executive Partner

    CAMBRIDGE, Mass., Dec. 16, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Paul Biondi to the post of Executive Partner. Mr. Biondi most recently

  2. Flagship Pioneering Unveils Cellarity, the First Company to Discover Medicines Targeting Cell Behavior

    CAMBRIDGE, Mass., Dec. 10, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, unveiled Cellarity, a first-of-its-kind therapeutics company that is discovering and developing medicines

  3. Evelo Biosciences Appoints Juan Andres to Board of Directors

    CAMBRIDGE, Mass., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today

  4. Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award

    CAMBRIDGE, Mass., Dec. 2, 2019 /PRNewswire/ -- Flagship Pioneering has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award recognizes Nancy Simonian, M.D., CEO of Syros

  5. Evelo Biosciences to Present at the Stifel 2019 Healthcare Conference

    CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1b data due 1Q 2020.
EDP1066
Psoriasis or atopic dermatitis
Phase 2a trial ongoing - no longer providing guidance as to timing of data.
EDP1503 and KEYTRUDA (pembrolizumab)
Melanoma
Phase 2 trial to be initiated 2Q 2020 with initial data due late 2020.
EDP1815
Psoriasis and Atopic Dermatitis
Phase 1/2 initial data due 1H 2020.
EDP1503 and KEYTRUDA (pembrolizumab)
Colorectal cancer; Triple-negative breast cancer
Phase 1b data due 2Q 2020.
EDP1815
Atopic dermatitis and Psoriasis
Phase 1b trial to be initiated 2H 2020.
EDP1867
Asthma

Latest News

  1. Flagship Pioneering Strengthens Leadership With Appointment of Paul Biondi as Executive Partner

    CAMBRIDGE, Mass., Dec. 16, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Paul Biondi to the post of Executive Partner. Mr. Biondi most recently

  2. Flagship Pioneering Unveils Cellarity, the First Company to Discover Medicines Targeting Cell Behavior

    CAMBRIDGE, Mass., Dec. 10, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, unveiled Cellarity, a first-of-its-kind therapeutics company that is discovering and developing medicines

  3. Evelo Biosciences Appoints Juan Andres to Board of Directors

    CAMBRIDGE, Mass., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today

  4. Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award

    CAMBRIDGE, Mass., Dec. 2, 2019 /PRNewswire/ -- Flagship Pioneering has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award recognizes Nancy Simonian, M.D., CEO of Syros

  5. Evelo Biosciences to Present at the Stifel 2019 Healthcare Conference

    CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today

  6. Evelo Biosciences to Present Preclinical Data from its EDP1503 Oncology Program at the Society for Immunotherapy of Cancer's (SITC) Annual Meeting

    CAMBRIDGE, Mass., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences (NASDAQ:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced

  7. Flagship Pioneering Unveils Cygnal Therapeutics

    CAMBRIDGE, Mass., Oct. 8, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today unveiled Cygnal Therapeutics. Founded in 2017 in Flagship Labs, Flagship's innovation foundry,

  8. Evelo Biosciences to Present at the 2019 Cantor Global Healthcare Conference

    CAMBRIDGE, Mass,, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, today announced that

  9. Flagship Pioneering Unveils Omega Therapeutics and Appoints Seasoned BioPharma Executive Mahesh Karande as President and Chief Executive Officer

    Omega Therapeutics is unleashing the human genome's native capacity to regulate genes and cure disease for a new era of genomic medicine The Company's platform is focused on precise tuning of Insulated Genomic

  10. Evelo Biosciences to Host Key Opinion Leader Symposium on Unmet Need in Mild to Moderate Psoriasis and Potential for EDP1815

    CAMBRIDGE, Mass., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, today announced that it

  11. Evelo Biosciences to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects,